Unibest

Pharmaceutical intermediates

Momelotinib Dihydrochloride Monohydrate Intermediates

2 pharmaceutical intermediates for Momelotinib Dihydrochloride Monohydrate. Indication: Myelofibrosis.

提交项目All intermediates

About Momelotinib Dihydrochloride Monohydrate

Originator
Glaxosmithkline Llc; Gilead Sciences Inc
Indication
Myelofibrosis
Approved Date
09/15/2023
NCE Patent
09/15/2028
DS/DP
01/03/2030

Available intermediates

2 intermediates currently listed for Momelotinib Dihydrochloride Monohydrate. Request specifications, documentation or a quotation for any item below.

Momelotinib Dihydrochloride Monohydrate intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
4-(2-(4-MorpholinophenylaMino)pyriMidin-4-yl)benzoic acid945749-71-3//
4-Morpholinophenylguanidine247234-41-9//

Other programs under M

MaribavirMaxacalcitolMetoclopramide HClMicafungin SodiumMilvexianMirogabalin besilateMolnupiravirMoxifloxacin hydrochloride

Building toward Momelotinib Dihydrochloride Monohydrate?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →